FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004232421> ?p ?o ?g. }

• W2004232421 endingPage "56" @default.
• W2004232421 startingPage "49" @default.
• W2004232421 abstract "Suramin, a polysulfonated naphthylurea, inhibits the actions of polypeptide growth factors including acidic and basic fibroblast growth factors (aFGF and bFGF), which confer broad spectrum chemotherapy resistance. We hypothesized that suramin at non-cytotoxic doses in combination with weekly paclitaxel would be well tolerated and demonstrate anti-tumor activity.Women with metastatic breast cancer who had been previously treated with a taxane in the adjuvant or metastatic setting were eligible. The primary objective of the phase I was to determine the dose of intravenous (IV) weekly suramin that resulted in plasma concentrations between 10 and 50 umol/l over 8-48 h (or the target range) in combination with IV 80 mg/m(2) of weekly paclitaxel. The primary objective of the phase II trial was to determine the anti-tumor activity of the dosing regimen defined in phase I. Therapy was continued until disease progression or development of unacceptable toxicity.Thirty-one patients were enrolled (9: phase I; 22: phase II). In phase I, no dose-limiting toxicities were observed. Pharmacokinetics during the first cycle showed suramin concentrations within the target range for 21 of 24 weekly treatments (88 %). In phase II, the objective response rate (ORR) was 23 % (95 % CI 8-45 %), the median progression-free survival was 3.4 months (95 % CI 2.1-4.9 months), and the median overall survival was 11.2 months (95 % CI 6.6-16.0 months).Non-cytotoxic doses of suramin in combination with weekly paclitaxel were well tolerated. The efficacy was below the pre-specified criteria required to justify further investigation." @default.
• W2004232421 created "2016-06-24" @default.
• W2004232421 creator A5012144114 @default.
• W2004232421 creator A5019260167 @default.
• W2004232421 creator A5028000633 @default.
• W2004232421 creator A5033557142 @default.
• W2004232421 creator A5040460958 @default.
• W2004232421 creator A5051619378 @default.
• W2004232421 creator A5051867478 @default.
• W2004232421 creator A5055263245 @default.
• W2004232421 creator A5056680178 @default.
• W2004232421 creator A5057762207 @default.
• W2004232421 creator A5067587535 @default.
• W2004232421 creator A5068532143 @default.
• W2004232421 creator A5077645346 @default.
• W2004232421 creator A5084349853 @default.
• W2004232421 creator A5085031128 @default.
• W2004232421 creator A5086903918 @default.
• W2004232421 date "2012-05-22" @default.
• W2004232421 modified "2023-09-27" @default.
• W2004232421 title "Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes" @default.
• W2004232421 cites W1517390619 @default.
• W2004232421 cites W1946759281 @default.
• W2004232421 cites W1946819517 @default.
• W2004232421 cites W1989826195 @default.
• W2004232421 cites W1999896620 @default.
• W2004232421 cites W2014302365 @default.
• W2004232421 cites W2026322409 @default.
• W2004232421 cites W2045473735 @default.
• W2004232421 cites W2046359251 @default.
• W2004232421 cites W2057147067 @default.
• W2004232421 cites W2067997630 @default.
• W2004232421 cites W2083811717 @default.
• W2004232421 cites W2086918041 @default.
• W2004232421 cites W2095130406 @default.
• W2004232421 cites W2099990230 @default.
• W2004232421 cites W2100749093 @default.
• W2004232421 cites W2108321597 @default.
• W2004232421 cites W2110426068 @default.
• W2004232421 cites W2122696814 @default.
• W2004232421 cites W2126275851 @default.
• W2004232421 cites W2130942316 @default.
• W2004232421 cites W2136791645 @default.
• W2004232421 cites W2139248078 @default.
• W2004232421 cites W2140837341 @default.
• W2004232421 cites W2154142993 @default.
• W2004232421 cites W2157881618 @default.
• W2004232421 cites W2162736578 @default.
• W2004232421 cites W2163003060 @default.
• W2004232421 cites W2171769979 @default.
• W2004232421 cites W2259233362 @default.
• W2004232421 cites W2285183774 @default.
• W2004232421 cites W2419316411 @default.
• W2004232421 cites W4254140658 @default.
• W2004232421 doi "https://doi.org/10.1007/s00280-012-1887-x" @default.
• W2004232421 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3466596" @default.
• W2004232421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22729159" @default.
• W2004232421 hasPublicationYear "2012" @default.
• W2004232421 type Work @default.
• W2004232421 sameAs 2004232421 @default.
• W2004232421 citedByCount "20" @default.
• W2004232421 countsByYear W20042324212013 @default.
• W2004232421 countsByYear W20042324212014 @default.
• W2004232421 countsByYear W20042324212015 @default.
• W2004232421 countsByYear W20042324212016 @default.
• W2004232421 countsByYear W20042324212017 @default.
• W2004232421 countsByYear W20042324212018 @default.
• W2004232421 countsByYear W20042324212019 @default.
• W2004232421 countsByYear W20042324212020 @default.
• W2004232421 countsByYear W20042324212021 @default.
• W2004232421 countsByYear W20042324212022 @default.
• W2004232421 crossrefType "journal-article" @default.
• W2004232421 hasAuthorship W2004232421A5012144114 @default.
• W2004232421 hasAuthorship W2004232421A5019260167 @default.
• W2004232421 hasAuthorship W2004232421A5028000633 @default.
• W2004232421 hasAuthorship W2004232421A5033557142 @default.
• W2004232421 hasAuthorship W2004232421A5040460958 @default.
• W2004232421 hasAuthorship W2004232421A5051619378 @default.
• W2004232421 hasAuthorship W2004232421A5051867478 @default.
• W2004232421 hasAuthorship W2004232421A5055263245 @default.
• W2004232421 hasAuthorship W2004232421A5056680178 @default.
• W2004232421 hasAuthorship W2004232421A5057762207 @default.
• W2004232421 hasAuthorship W2004232421A5067587535 @default.
• W2004232421 hasAuthorship W2004232421A5068532143 @default.
• W2004232421 hasAuthorship W2004232421A5077645346 @default.
• W2004232421 hasAuthorship W2004232421A5084349853 @default.
• W2004232421 hasAuthorship W2004232421A5085031128 @default.
• W2004232421 hasAuthorship W2004232421A5086903918 @default.
• W2004232421 hasBestOaLocation W20042324212 @default.
• W2004232421 hasConcept C112705442 @default.
• W2004232421 hasConcept C121608353 @default.
• W2004232421 hasConcept C126322002 @default.
• W2004232421 hasConcept C143998085 @default.
• W2004232421 hasConcept C170493617 @default.
• W2004232421 hasConcept C2775930923 @default.
• W2004232421 hasConcept C2776182878 @default.
• W2004232421 hasConcept C2776694085 @default.
• W2004232421 hasConcept C2777292972 @default.

• next